Clinical Trial Update: Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating dulaglutide, a GLP-1 receptor agonist, for severe intracranial atherosclerosis with ischemic stroke; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracranial Atherosclerosis
• Stroke

Drugs mentioned

• Dulaglutide (dulaglutide)

Snippet

Sponsor: National University of Singapore | Conditions: Intracranial Atherosclerosis, Stroke, Ischemic | Phase 2, Phase 3 | Status: RECRUITING